United Asset Strategies Inc. Has $660,000 Stock Holdings in Medtronic PLC $MDT

United Asset Strategies Inc. trimmed its holdings in Medtronic PLC (NYSE:MDT) by 8.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,573 shares of the medical technology company’s stock after selling 707 shares during the period. United Asset Strategies Inc.’s holdings in Medtronic were worth $660,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC raised its stake in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after buying an additional 37,265 shares during the period. Edgestream Partners L.P. purchased a new position in shares of Medtronic in the 1st quarter worth about $325,000. Signaturefd LLC lifted its holdings in shares of Medtronic by 14.3% in the 1st quarter. Signaturefd LLC now owns 14,325 shares of the medical technology company’s stock worth $1,287,000 after acquiring an additional 1,797 shares during the last quarter. Wealthfront Advisers LLC boosted its position in Medtronic by 38.7% during the first quarter. Wealthfront Advisers LLC now owns 86,005 shares of the medical technology company’s stock valued at $7,728,000 after buying an additional 24,000 shares during the period. Finally, Sage Mountain Advisors LLC bought a new stake in shares of Medtronic in the 1st quarter valued at about $266,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Stock Up 0.4%

Shares of MDT stock opened at $95.79 on Thursday. The stock’s fifty day moving average price is $94.31 and its 200 day moving average price is $90.22. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $99.37. The company has a market cap of $122.86 billion, a price-to-earnings ratio of 26.39, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. During the same quarter last year, the company posted $1.23 earnings per share. The business’s quarterly revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Medtronic

In related news, Director William R. Jellison acquired 2,500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was acquired at an average price of $92.37 per share, with a total value of $230,925.00. Following the acquisition, the director directly owned 5,000 shares in the company, valued at $461,850. This represents a 100.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.26% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on MDT shares. Citigroup boosted their target price on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Mizuho lifted their price objective on Medtronic from $98.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Argus raised their price objective on Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, August 26th. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research report on Thursday, August 14th. Finally, Wells Fargo & Company upped their target price on shares of Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $102.82.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.